Median Technologies announces today the results of a preliminary retrospective study on the evaluation of the risk of recurrence for patients with primary liver cancer (HCC – hepatocellular carcinoma) based on a non-invasive biomarker.
Read moreMedian Technologies (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19. Revenue of €2.8m, +47% compared with the first quarter of 2019; Order backlog of €44.4m, +€6.1m compared with December 31, 2019; Median Technologies at the service of biopharmaceutical companies involved in Covid-19 clinical trials.
Read moreThe disbursement improves the Company’s financial visibility. It will help accelerate the investment program for the iBiopsy® imaging platform developed by Median Technologies. The Company provides outlook for the iBiopsy® program for 2020.
Read moreMedian Technologies reports full year 2019 financial results: Revenue of €9m as of December 31, 2019, an increase of 41% compared with revenue for 2018; Order backlog of €38.3m, +61.6% compared with December 31, 2018; Cash and cash equivalents of €7.6m
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]